Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness

John Politis, Brian Le, Natasha Smallwood
European Respiratory Journal 2017 49: 1601858; DOI: 10.1183/13993003.01858-2016
John Politis
1Dept of Respiratory Medicine, The Royal Melbourne Hospital, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Le
2Palliative and Supportive Care, The Royal Melbourne Hospital, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Smallwood
1Dept of Respiratory Medicine, The Royal Melbourne Hospital, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Natasha.smallwood@mh.org.au
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Respiratory depression secondary to morphine use in COPD patients with refractory breathlessness http://ow.ly/8NVw30aLZXv

To the Editor:

Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction and progressive respiratory failure. Patients develop increasing breathlessness, which can persist despite optimal medical management (refractory chronic breathlessness) [1]. Various studies suggests that low-dose morphine may safely reduce refractory breathlessness in patients with advanced respiratory disease [2–6]; however, the recent population cohort study by Vozoris et al. [7] in the European Respiratory Journal suggests opioids may be associated with increased adverse respiratory outcomes, including death in older COPD patients. We report a case of respiratory depression secondary to opioid use for refractory breathlessness.

A 69-year-old man with severe COPD (forced expiratory volume in 1 s 0.8 L (25% predicted), forced vital capacity 3.2 L (75% predicted) and diffusing capacity of the lung for carbon monoxide 9 mL·min−1·mmHg−1 (30% predicted)) was admitted to our hospital with an infective exacerbation. Prior to admission, he had been an infrequent exacerbator and was known to have had severe, exertional breathlessness for a few years (Modified Medical Research Council Breathlessness Score of 3 out of 4). He had a very limited exercise capacity (6-min walk test distance 90 m with desaturation from SpO2 92% to 87% at 3 min), requiring ambulatory oxygen therapy. His usual COPD management included tiotropium (18 μg daily), budesonide/formoterol (200/6 μg, two puffs twice daily) and salbutamol (as required). He was not receiving domiciliary noninvasive positive pressure ventilation (NIV). He had previously completed a pulmonary rehabilitation programme but was not engaged in an exercise programme immediately before the admission. He also had multiple medical comorbidities, including ischaemic heart disease, hypertension, dyslipidaemia and anxiety.

The patient presented to hospital with increasing dyspnoea, fever and productive cough, and was found to have an elevated white cell count (23.2×109 per L) and C-reactive protein (58 mg·L−1). Renal function on admission was normal and remained stable during the admission. A chest radiograph did not demonstrate any focal consolidation. The patient was treated with hydrocortisone, benzylpenicillin, doxycycline, supplemental oxygen and regular nebulised salbutamol; however, NIV (arterial blood gas carbon dioxide tension 37 mmHg) was not required.

Despite optimal treatment for the exacerbation, on day 4, the patient had severe, distressing breathlessness at rest. He was therefore referred to a specialist palliative care department, which recommended regular, long-acting, oral morphine (10 mg mane and 5 mg nocte) with immediate-release morphine (2–3 mL of 1-mg· mL−1 solution) as required every 4–6 h for breakthrough breathlessness. Only 5 mg immediate-release morphine in total were required over the remaining 4 days of the admission. His dyspnoea was subsequently better controlled, with no signs of respiratory depression.

After 8 days in hospital, the patient was discharged home, where he lived alone, using the same morphine regimen for breathlessness. Laxatives were prescribed to prevent constipation. Verbal and written education regarding his medications was provided by a pharmacist prior to discharge. Follow-up in the respiratory clinic was arranged for 6 weeks later and he was advised to see his general practitioner (GP) in the interim.

9 days later, the patient visited his GP, who found him drowsy and confused with respiratory depression. The GP administered naloxone and the patient was transferred to the hospital. In the emergency department, the patient had ongoing drowsiness and respiratory depression, requiring further naloxone. It became apparent that the patient had confused the laxative liquid and immediate-release morphine, and therefore had inadvertently consumed 30 mg morphine solution in addition to 10 mg extended-release morphine prior to visiting his GP.

The patient was monitored in a high-dependency unit, where he remained clinically stable and was discharged the following day. Despite further medication education, he could not safely self-administer immediate-release morphine; therefore, this was discontinued. Long-acting morphine twice daily was continued on discharge for his breathlessness.

This case highlights many important issues. The patient described had chronic severe breathlessness, which of itself may have been amenable to opioid treatment. However, opioid treatment was first indicated in the context of worsening breathlessness during an infective exacerbation. It is well recognised that the best treatment for breathlessness is to treat any underlying, reversible causes, such as infection. Thus, it is likely that with treatment for the patient's infection and with time, his breathlessness would have improved to baseline. Consequently, whilst morphine may have been appropriate during his admission, his longer-term morphine requirement and dosage were unknown.

Many international COPD guidelines recommend opioids to palliate distressing breathlessness in patients with advanced disease [8, 9]; however, currently, no guidelines suggest initiating opioids during an exacerbation. In COPD frequent exacerbators, 14–18% of first opioid prescriptions occur in the context of a respiratory exacerbation [10], despite a recent exacerbation being an exclusion criteria in opioid clinical trials.

In this case, respiratory depression occurred due to a significant patient dosing administration error, with the patient inadvertently consuming 10 times his prescribed, as-needed, immediate-release morphine dose. Dosing errors are well-recognised serious, adverse events; however, many COPD patients are older, live alone, have significant comorbidity and use multiple medications, any of which may increase the risk of serious toxicity or dosing error. Comorbidities, such as dementia and glaucoma, that can lead to patent dosing administration error occur more frequently in patients with COPD [11, 12], and individuals with cognitive comorbidities have been excluded from opioids breathlessness clinical trials [2, 3].

The US Food and Drug Administration recently announced new safety labelling changes for immediate-release opioids prescribed for pain, warning about the serious risks including addiction, overdose and death [13]. Off-license prescription of opioids for breathlessness requires even greater vigilance regarding serious events. Options for initiating morphine for refractory breathlessness include long-acting morphine (10 mg daily with up-titration weekly) [3] or immediate-release morphine (0.5 mg twice daily with up-titration weekly) [14]. However, the regimen for both immediate-release and long-acting morphine, which was used in this case and which is commonly used for pain, has not been studied in breathlessness trials. As the optimal morphine regimen for breathlessness is unknown, long-term morphine prescription requires careful consideration of risks and benefits, and dosing should be individualised using the lowest dose possible with up and down-titration according to response and side effects [15].

Similarly, when morphine is prescribed off-license, comprehensive medication education and ongoing, effective communication with the patient, family and other health professionals are essential. Initiating treatment as a stable outpatient, with close supervision and early review within 1–2 weeks (and not after 6 weeks as occurred in this case), allow these issues to be addressed, without the time pressures and often multiple medication changes, which may occur as an inpatient.

While morphine has a role in palliating refractory breathlessness, the additional complexity and challenges of off-label morphine prescription to respiratory patients reinforce the urgent need for further research in this clinical setting. In the interim, when considering morphine for patients with advanced respiratory disease and refractory breathlessness, we should remember, “first, do no harm”.

Acknowledgements

The authors would like to thank the patients and staff of the Respiratory Dept at the Royal Melbourne Hospital, Parkville, Australia.

Footnotes

  • Conflict of interest: None declared.

  • Received September 20, 2016.
  • Accepted February 12, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Burdon JG,
    2. Pain MC,
    3. Rubinfield AR, et al.
    Chronic lung diseases and the perception of breathlessness: a clinical perspective. Eur Respir J 1994; 7: 1342–1349.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Abernethy AP,
    2. Currow DC,
    3. Frith P, et al.
    Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523–528.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Currow DC,
    2. McDonald C,
    3. Oaten S, et al.
    Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42: 388–399.
    OpenUrlCrossRefPubMedWeb of Science
    1. Currow DC,
    2. Plummer J,
    3. Frith P, et al.
    Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 2007; 10: 1031–1036.
    OpenUrlCrossRefPubMed
    1. Jennings AL,
    2. Davies AN,
    3. Higgins JP, et al.
    A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939–944.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Ekstrom MP,
    2. Bornefalk-Hermansson A,
    3. Abernethy AP, et al.
    Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Vozoris NT,
    2. Wang X,
    3. Fischer H, et al.
    Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016; 48: 683–693.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Parshall MB,
    2. Schwartzstein RM,
    3. Adams L, et al.
    An official American Thoracic Society statement: updated on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Lanken PN,
    2. Terry PB,
    3. Delisser HM, et al.
    An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912–927.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Vozoris NT,
    2. Wang X,
    3. Fischer HD, et al.
    Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol 2016; 81: 161–170.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Liao WC,
    2. Lin CL,
    3. Chang SN, et al.
    The association between chornic obstructive pulmonary disease and dementia: a population-based retrospective cohort study. Eur J Neurol 2015; 22: 334–340.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Sorianoa JB,
    2. Visick GT,
    3. Muellerova H, et al.
    Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099–2107.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    US Food and Drug Administration. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction overdose and death. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm Date last accessed: January 2017. Date last updated: March 22, 2016.
  12. ↵
    1. Rocker GM,
    2. Simpson AC,
    3. Young J, et al.
    Opioid therapy for refracotry dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open 2013; 1: E27–E36.
    OpenUrlCrossRef
  13. ↵
    1. Smallwood N,
    2. Le B,
    3. Currow D, et al.
    Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease. Intern Med J 2015; 45: 898–904.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 5 Table of Contents
European Respiratory Journal: 49 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness
John Politis, Brian Le, Natasha Smallwood
European Respiratory Journal May 2017, 49 (5) 1601858; DOI: 10.1183/13993003.01858-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness
John Politis, Brian Le, Natasha Smallwood
European Respiratory Journal May 2017, 49 (5) 1601858; DOI: 10.1183/13993003.01858-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Correspondence

  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society